Refametinib

Refametinib (BAY 86-9766; previously RDEA119) is a highly selective and potent orally available inhibitor of MEK 1 and MEK 2.  It displays potent in vitro and in vivo antitumor activity in multiple preclinical cancer models, including melanoma, colorectal cancer, non-small cell lung cancer, epidermal carcinoma, and HCC.